These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15914875)

  • 1. Daptomycin: a novel cyclic lipopeptide antimicrobial.
    Schriever CA; Fernández C; Rodvold KA; Danziger LH
    Am J Health Syst Pharm; 2005 Jun; 62(11):1145-58. PubMed ID: 15914875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin.
    Fenton C; Keating GM; Curran MP
    Drugs; 2004; 64(4):445-55; discussion 457-8. PubMed ID: 14969579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin - a novel antibiotic against Gram-positive pathogens.
    LaPlante KL; Rybak MJ
    Expert Opin Pharmacother; 2004 Nov; 5(11):2321-31. PubMed ID: 15500379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin: a review 4 years after first approval.
    Sauermann R; Rothenburger M; Graninger W; Joukhadar C
    Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens].
    Stefani S; Esposito S
    Infez Med; 2006 Dec; 14(4):179-96. PubMed ID: 17380085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin: a cyclic lipopeptide antimicrobial agent.
    Jeu L; Fung HB
    Clin Ther; 2004 Nov; 26(11):1728-57. PubMed ID: 15639687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin: a new drug class for the treatment of Gram-positive infections.
    Alder JD
    Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
    Hair PI; Keam SJ
    Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on daptomycin: the first approved lipopeptide antibiotic.
    Lee SY; Fan HW; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2006 Jul; 7(10):1381-97. PubMed ID: 16805723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin: a comparison of two intravenous formulations.
    Frankenfeld C; Mittal S; Melendez Y; Mendez-Vigo L; Lamp KC; Keller KN; Bertolami SR
    Drug Des Devel Ther; 2018; 12():1953-1958. PubMed ID: 29988771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin.
    Tedesco KL; Rybak MJ
    Pharmacotherapy; 2004 Jan; 24(1):41-57. PubMed ID: 14740787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin: a review of properties, clinical use, drug delivery and resistance.
    Vilhena C; Bettencourt A
    Mini Rev Med Chem; 2012 Mar; 12(3):202-9. PubMed ID: 22356191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.